Introduction {#s1}
============

Wholegrain, fish, and polyphenol rich foods, such as berries, are known to have beneficial effects on human health [@pone.0090352-Ye1]--[@pone.0090352-Basu1]. These food items are also part of the Nordic diet, which has recently raised a great interest. In an observational study, healthy Nordic food pattern has been shown to be associated with reduced mortality in adults [@pone.0090352-Olsen1]. In intervention studies improvements in cardiovascular and diabetic risk markers, especially low-grade inflammation, in high risk individuals have been reported [@pone.0090352-Adamsson1]--[@pone.0090352-Uusitupa1]. Overall, nutritional studies are shifting increasingly their focus from studying single nutrients or foods on the exploration of the whole dietary pattern. The Mediterranean diet is probably the best-known dietary pattern and has long been related to improved health and prevention of e.g. cardiovascular diseases (CVD) and type 2 diabetes [@pone.0090352-Sofi1]--[@pone.0090352-SalasSalvado1].

Epidemiological evidence is strong concerning the beneficial effects of consumption of fish on the prevention of coronary heart disease (CHD) progression and mortality [@pone.0090352-He1], [@pone.0090352-Harris1]. The hypotriglyceridemic effect of fish oil is also well documented, but the evidence has been obtained from trials using fish oil supplements and in larger amounts than currently recommended [@pone.0090352-Harris2], [@pone.0090352-Balk1]. Instead, there is no evidence of a secondary preventive effect of n-3 fatty acid supplements against overall cardiovascular events among patients with a history of cardiovascular disease [@pone.0090352-Kwak1]. The effect on glucose and insulin metabolism has been inconsistent, but possible adverse effects on glucose metabolism related to especially higher doses may be compensated by improved serum triglyceride concentration in diabetic subjects [@pone.0090352-Balk1], [@pone.0090352-Karlstrom1], [@pone.0090352-Akinkuolie1]. Recent controlled experimental studies have focused on the effects of supplemental long chain n-3 polyunsaturated fatty acids rather than the effects of dietary fish.

The use of metabolomics in nutrition-related research has made a significant impact on assessing novel biomarkers of dietary intake as well as analyses of intervention studies [@pone.0090352-Brennan1]. Mass spectrometry and proton nuclear magnetic resonance (NMR) spectroscopy are the two key experimental technologies in the field. NMR spectroscopy could provide information on lipoprotein subclass distribution and lipoprotein particle concentrations, low-molecular-weight metabolites as well as detailed molecular information on serum lipids [@pone.0090352-Soininen1], [@pone.0090352-Kettunen1]. It is suggested that besides the measurement of standard lipids, including total cholesterol, LDL cholesterol and HDL cholesterol concentrations, the measurement of specific HDL subclasses might help in evaluation of the risk of cardiovascular events [@pone.0090352-Pirillo1]. Increased concentration of large HDL particles has inverse association with the risk of coronary artery disease, while small HDL particles appear to be associated with increased risk [@pone.0090352-Pirillo1], [@pone.0090352-Arsenault1]. Lipid transfer proteins phospholipid transfer protein (PLTP) and cholesterol ester transfer protein (CETP) are among factors which modify HDL composition and also affect efficiency of HDL-mediated reverse cholesterol transport [@pone.0090352-Villard1]--[@pone.0090352-Vikstedt1]. HDL associated enzyme paraoxonase 1 (PON1) also is an important factor regulating anti-oxidative processes of lipoprotein particles, mainly LDL and HDL [@pone.0090352-Aviram1].

Few studies so far examined cross-sectional association between nutrients and lipoprotein subclasses suggest that alcohol, disaccharides, and n-3 PUFAs are associated with serum lipoprotein subclass distribution [@pone.0090352-Mukamal1]--[@pone.0090352-Annuzzi1]. Controlled trials have focused on n-3 PUFAs, mainly using supplements. Most studies investigating the effects of n-3 PUFAs or fatty fish on HDL particle subspecies have reported increases in large HDL particles and/or decreases of small HDL particles [@pone.0090352-Burillo1]. In our pilot study, fatty fish intake at least 4 times per week increased HDL particle size [@pone.0090352-Erkkil1]. Considering whole dietary patterns, positive associations have been reported between a high-fat, high-sucrose and low fiber dietary pattern (junk food) and concentrations of serum triglycerides (Tg) and small dense HDL particles, larger Tg-enriched VLDL particles and small dense LDL particles [@pone.0090352-Bogl2].

We have previously shown that a diet rich in whole grain and low insulin response grain products, fatty fish and berries alter plasma lipidomic profile and improves glucose metabolism and markers of endothelial function and inflammation [@pone.0090352-deMello1], [@pone.0090352-Lankinen1]. In the present secondary analyses of the same trial, we take the advantage of the comprehensive information provided by the new serum NMR-based metabolomics platform and examine the combined effects of these food items on the systemic metabolic profiles and lipid transfer protein activities in subjects with the metabolic syndrome. Furthermore, we study the associations between the changes in fish intake and changes in variables related to large HDL particles, and cross-sectional correlations between the lipid transfer protein activities and variables related to large HDL particles, and between average diameter of HDL and LDL particles and serum Tg.

Materials and Methods {#s2}
=====================

Ethics statement {#s2a}
----------------

The participants volunteered to the study and gave their written informed consent. The study plan was approved by the Research Ethics Committee, Hospital District of Northern Savo. The intervention was performed in accordance of Helsinki Declaration.

The study was registered at ClinicalTrials.gov NCT00573781. The trial was registered after participants' recruitment began. The registration was delayed, because of the fact that the procedure of trial registration had just began to be a common practice at that time (2007), and we were not aware of the details related to the time limits. However, we did not start recruitment before the study plan was approved by the Research Ethics Committee. The trial was registered before the intervention began.

The protocol for this trial and completed CONSORT checklist are available as supporting information; See [Checklist S1](#pone.0090352.s003){ref-type="supplementary-material"} and [Protocol S1](#pone.0090352.s006){ref-type="supplementary-material"}. The data is available from authors.

Subjects {#s2b}
--------

Altogether 131free-living subjects of Caucasian origin were recruited into a 12-week parallel controlled dietary intervention trial via advertisements in the local newspaper in Kuopio area. The trial was conducted at the Department of Clinical Nutrition, University of Eastern Finland (Kuopio, Finland). Recruitment and screening were done during October 2007 - November 2008, and intervention periods were carried out during January 2008 - June 2009. The inclusion criteria were age 40--70 years, impaired glucose metabolism (fP-gluc 5.6--6.9 mmol/l or in OGTT 2 hour P-gluc 7.8--11.0 mmol/l) and two of the following: BMI 26--39 kg/m^2^, waist circumference \>102 cm in men and \>88 cm in women, serum Tg \>1.7 mmol/l, HDL \<1.0 mmol/l in men and \<1.3 mmol/l in women or blood pressure ≥130 or ≥85 mmHg (NCEP Adult Treatment Panel III, 2001). After a baseline period of two weeks with unchanged diet and lifestyle habits, the subjects were randomized by study nurse into three groups; HealthyDiet, Wholegrain Enriched Diet (WGED) or Control. The randomization was conducted based on a randomization table by matching the subjects according to gender and medians of age, fP-gluc and BMI of the study population at screening so that from every division of randomizing factors (gender-\>age-\>BMI-\>fP-glucose) it was possible to end up to any of the three study groups. The matching produced equal amounts of certain strata classes among the groups. Altogether 106 subjects completed the study ([Figure 1](#pone-0090352-g001){ref-type="fig"}). Serum samples for a high-throughput ^1^H-NMR analyses were available from 105 participants. The drop outs did not differ in clinical characteristics except they were younger than the completers (55±8 vs. 59±7 years, mean ± SD, p =  0.023).

![Flow chart of the study.\
Adapted from De Mello et al [@pone.0090352-deMello1].](pone.0090352.g001){#pone-0090352-g001}

Baseline characteristics of the subjects are presented in [Table 1](#pone-0090352-t001){ref-type="table"}. Of all subjects, 86% had at least one medication. Subjects were asked to continue their medication unchanged throughout the study. Of all subjects, 27% used statins. The use of statins or other medication did not differ between the groups. Detailed information about the medication of the participants has been reported earlier [@pone.0090352-Lankinen1].

10.1371/journal.pone.0090352.t001

###### Clinical characteristics at baseline and at the end of the intervention period (mean ± SD).

![](pone.0090352.t001){#pone-0090352-t001-1}

                                          HealthyDiet n = 37   WGED n = 34   Control n = 35                                                                 
  -------------------------------------- -------------------- ------------- ---------------- ------- ------------ ------------ ------- ------- ------------ -----------
  **Body mass index (kg/m^2^)**                31.1±3.6         30.9±3.4         0.860        0.966    31.4±3.4     31.4±3.4    0.171   0.675    31.0±3.6    31.2±3.7
  **Waist circumference (cm)**                105.6±9.5         105.0±9.1        0.008        0.091   106.3±11.1   105.9±11.4   0.034   0.406   105.8±10.0   106.3±9.8
  **Systolic blood pressure (mmHg)**            137±13           132±13          0.453        0.833     135±16       133±15     0.453   0.805     139±12      135±13
  **Diastolic blood pressure (mmHg)**            89±7             86±7           0.596        0.833      86±8         84±7      0.592   0.833      88±7        86±6
  **Serum total cholesterol (mmol/l)**         5.1±0.9           5.2±0.8         0.396        0.793    5.1±1.0      5.3±1.1     0.160   0.675    5.4±1.0      5.4±1.0
  **LDL cholesterol (mmol/l)**                 3.1±0.7           3.1±0.7         0.804        0.953    3.2±0.8      3.2±0.9     0.334   0.712    3.4±0.8      3.4±0.8
  **HDL cholesterol (mmol/l)**                 1.3±0.3           1.3±0.3         0.966        0.966    1.2±0.4      1.2±0.4     0.919   0.966    1.3±0.3      1.3±0.3
  **Serum triglycerides (mmol/l)**             1.6±0.6           1.7±0.8         0.250        0.712    1.5±0.8      1.7±1.0     0.951   0.966    1.5±0.8      1.6±0.7
  **Serum ApoA-1 (g/l)**                       1.5±0.2           1.5±0.2         0.673        0.847    1.4±0.3      1.4±0.3     0.706   0.847    1.4±0.2      1.4±0.2
  **Serum ApoB100 (g/l)**                      1.1±0.2           1.1±0.2         0.867        0.867    1.1±0.3      1.1±0.3     0.487   0.847    1.1±0.3      1.1±0.3
  **ApoB100/Apo A-1**                         0.72±0.17         0.71±0.16        0.570        0.847   0.79±0.21    0.77±0.19    0.671   0.847   0.81±0.22    0.79±0.23
  **Fasting plasma glucose (mmol/l)**          6.1±0.5           6.1±0.5         0.728        0.932    6.1±0.4      6.1±0.5     0.506   0.833    6.2±0.5      6.2±0.5
  **2-h plasma glucose (mmol/l)**              6.7±1.7           6.0±1.8         0.099        0.530    6.6±1.6      6.1±1.9     0.211   0.675    6.8±1.9      6.7±2.2
  **Serum insulin (mU/l)**                     11.7±5.9         12.5±6.3         0.624        0.833    12.0±6.2     13.7±8.0    0.316   0.712    13.0±6.7    13.2±6.3
  **PLTP activity (nmol/ml/h)**               7288±1686         7249±1560        0.750        0.947   7489±1958    7339±1609    0.947   0.947   6985±1353    6921±1522
  **CETP activity (nmol/ml/h)**                25.8±6.9         25.4±6.9         0.607        0.947    24.9±6.3     25.1±6.0    0.719   0.947    25.9±7.4    25.8±6.9
  **PON-1 activity (µmol/min)**               26.6±24.0         25.3±21.7        0.890        0.947   29.0±24.4    27.8±23.4    0.881   0.947   21.3±16.0    20.4±14.1

Based on a mixed model comparison, where the interaction of time and group compared to Controls (time\*group) is analyzed.

Diets {#s2c}
-----

In the HealthyDiet group (n = 37), the subjects replaced their habitual grain products with whole grain breads and a bread with low postprandial insulin response as previously reported [@pone.0090352-Lankinen1]. In brief, these products covered 20--25% of total energy intake and were delivered to the subjects. The fiber contents of the breads were 6.9% (endosperm rye bread), 6.4% (wholegrain wheat bread) and 10--14% (commercial whole grain rye breads). One portion of habitually used grain product, e.g. a slice of low fiber wheat bread, was allowed daily to increase compliance. Pasta with the fiber content of 6% was delivered as well and it was instructed to be consumed at the dose equal to 3.5 deciliter of uncooked pasta per week. The subjects were instructed to eat fatty fish (á 100--150 g) three times a week. Fish was reimbursed to the subjects. Bilberries were instructed to be consumed three portions per day (one portion corresponding to 100 g of fresh bilberries). Bilberries were delivered as whole frozen berries, frozen berry pure and berry powder made of whole berries without added sugar. Other berries were allowed to be consumed 3--4 portions (á ≤1 dl) per week.

In the WGED group (n =  34) the subjects consumed the same grain products as in the HealthyDiet group. In addition, the subjects could voluntarily have a wholegrain oat snack (8--8.5% dietary fiber) 1 portion per day. Eating habits regarding fish and berries were asked to be kept unchanged.

In the Control group (n = 35) the subjects replaced their habitually used grain products with refined wheat breads (dietary fiber 3--4.3 g/100 g) and other low fiber products (\<6% dietary fiber) which were delivered to the subjects. Maximum 1--2 portions of rye products were allowed per day. Bilberries were not allowed and other berries were allowed maximum 3--4 portions per week. A fish meal was allowed not more than once a week.

Other eating and lifestyle habits were asked to be kept unchanged. Alcohol use, physical exercise and medications were asked at screening, in the beginning and at the end of the study using a structured questionnaire. Dietary intake was monitored by 4-d food records which were kept during the run in period and three times during the intervention period at the 3^rd^, 7^th^ and 11^th^ week of the intervention. The recording dates were given by the study personnel and were either from Wednesday to Saturday or from Sunday to Wednesday. Nutrica® dietary intake analysis software (v. 2.5) was used for calculations. It is based on Finnish food composition analyses and international food composition tables. In addition to the food records, the subjects in all groups kept consumption records regarding the intake of fish, grain products and berries throughout the intervention to ensure compliance. These records were checked each time the subjects reported to the study center (every 1 to 2 weeks). Besides the daily records, the intake of fish was calculated manually based on 4-d food records.

Biochemical analyses {#s2d}
--------------------

Fasting samples for biochemical analyses were drawn from an antecubital vein. Methods for an oral glucose tolerance test (OGTT), plasma glucose, serum insulin, serum cholesterol and serum Apo A-1 and ApoB100 analyses are described in supplementary text ([Method S1](#pone.0090352.s005){ref-type="supplementary-material"}).

Serum NMR Metabolomics {#s2e}
----------------------

We applied proton NMR spectroscopy to determine the serum metabolome via 3 different molecular windows [@pone.0090352-Soininen1], [@pone.0090352-Kettunen1]. These windows provide information on 14 lipoprotein subclasses and lipoprotein particle concentrations (LIPO), low-molecular-weight metabolites such as amino acids, 3-hydroxybutyrate, and creatinine (LMWM), and detailed molecular information on serum lipids including free and esterified cholesterol, sphingomyelin, saturation degree and ω-3 fatty acids (LIPID). The methodology provides information on \>100 primary metabolic measures and multiple derived variables with clear biochemical interpretation and significance [@pone.0090352-Kettunen1], [@pone.0090352-Wang1]. The LIPO+LMWM data are run from native serum samples in the same experiment and the LIPID from the lipid extracts afterwards. The experimental protocol including sample preparation and NMR spectroscopy are described in detail in Inouye et al. [@pone.0090352-Inouye1]. The definition of the lipoprotein subclasses is as follows: chylomicrons and largest VLDL particles (average particle diameter at least 75 nm); five different VLDL subclasses: very large VLDL (average particle diameter of 64.0 nm), large VLDL (53.6 nm), medium VLDL (44.5 nm), small VLDL (36.8 nm), and very small VLDL (31.3 nm); intermediate-density lipoprotein (IDL) (28.6 nm); three LDL subclasses: large LDL (25.5 nm), medium LDL (23.0 nm), and small LDL (18.7 nm); and four HDL subclasses: very large HDL (14.3 nm), large HDL (12.1 nm), medium HDL (10.9 nm), and small HDL (8.7 nm). The following components of the lipoprotein particles were quantified: phospholipids, Tg, cholesterol, free cholesterol, and cholesterol esters. Due to resolution and concentration issues all of these components are not available for every subclass [@pone.0090352-Wurtz1]. The complete list of quantified metabolic measures is given in Supplemental [Table S1](#pone.0090352.s002){ref-type="supplementary-material"}. This quantitative platform has recently been applied in various large-scale epidemiological and genetic studies [@pone.0090352-Wang1]--[@pone.0090352-Chambers1]. Serum samples for NMR spectroscopy were available at baseline and at the end of the intervention from 105 participants. Thus 210 samples were originally processed, but 12 samples were lost due to experimental problems.

PLTP, CETP and PON1 {#s2f}
-------------------

Radiometric methods were used to analyze CETP [@pone.0090352-Groener1] and PLTP activities [@pone.0090352-Jauhiainen1]. Serum PON1 activity was measured using paraoxon as a substrate [@pone.0090352-Kleemola1].

Statistical analyses {#s2g}
--------------------

Based on primary aim of seeing changes in glucose metabolism, the power calculations were calculated based on fasting glucose. By using test significance α-level 0.05, 80% power, SD 0.4665 for variability, aim to see 5% difference between the groups in fasting glucose and power analysis method for two-sample t-test, the appropriate sample size was 37 per group. Statistical analyses were performed using the IBM SPSS statistical software (v. 19, SPSS Inc., Chicago, IL), R Project for Statistical Computing version 2.7.2 [@pone.0090352-R1] and nlme R-package version 3.1--96 [@pone.0090352-Pinheiro1]. Linear mixed-effect models were used to analyse group differences in the baseline and during the intervention. Quantitative dependent variables were transformed to base-10 logarithmic scale to account for non-normal distributions. Selected confounding phenotypes (gender, age, fasting glucose, BMI, cholesterol lowering medication, diuretic medication and smoking, were included in the models as covariates when studying changes in the NMR-based metabolic measures and subject identifiers were included as a grouping random effect. Interaction term between group and intervention time-point (before or after intervention) was used to examine group related changes during the intervention. Control group was used as a reference group when comparing group differences. Benjamini--Hochberg false discovery rate (FDR) was used to adjust the metabolomics measures and dietary intake results for multiple comparisons [@pone.0090352-Benjamini1]. Adjustment was done by one treatment effect at a time and in clinically relevant sets. FDR-adjusted p-value ≤ 0.05 was considered as statistically significant. All these analyses are secondary though aimed to be done in the original study protocol. The primary aim of the study was to examine effects on glucose metabolism [@pone.0090352-deMello1], [@pone.0090352-Lankinen1].

Associations between the changes in fish intake and changes in variables related to large HDL particles were tested using analyses of covariance (ANCOVA). Intervention group, age, gender, BMI and fasting glucose were included into models. Analyses were performed using standardized variables. Differences between the fish intake tertiles were tested using one-way ANOVA and Bonferroni post hoc comparisons. Baseline associations were studied applying linear regression model including age, gender, BMI and fasting glucose into models.

Results {#s3}
=======

Clinical characteristics {#s3a}
------------------------

The gender and age distributions of the study subjects were similar in all three groups [@pone.0090352-deMello1], [@pone.0090352-Lankinen1]. The average age was 58±7, 58±8 and 59±7 years, and the gender distribution (male/female) was 17/20, 17/17 and 18/17 in the HealthyDiet, WGED and Control group, respectively. [Table 1](#pone-0090352-t001){ref-type="table"} shows the clinical characteristics at baseline and at the end of the intervention. There were no significant differences in the characteristics between the groups at baseline or at the end of the intervention.

Dietary intake {#s3b}
--------------

In the HealthyDiet group, average fish consumption was 3.3 fish meals per week (67 g per day). Mostly used fish species were salmon, rainbow trout, vendace and Baltic herring. The average consumption of delivered bilberries and breads was 3.2 portions and 7.7 portions per day, respectively. The average consumption of the delivered breads was 7.9 portions in the WGED group and 6.8 portions in the Control group per day. The average fish intake was 42 g and 16 g per day in the WGED and in the Control group, respectively.

At baseline, the intake of dietary fiber was higher in the HealthyDiet group than in the WGED and Control groups (FDR p = 0.013). There were no other differences in the dietary intake at baseline. Dietary intake is presented in [Table 2](#pone-0090352-t002){ref-type="table"}. In the HealthyDiet group, eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and α-linolenic acid intakes increased while in the Control group the intake of PUFA, EPA and DHA decreased. The decrease of SFA intake in the Healthy Diet group compared to Control group was nearly significant (FDR p =  0.09). In the WGED group, the intake of total fat decreased, but there was no change in the quality of dietary fat. Fiber intake increased in both HealthyDiet and WGED groups whereas it decreased in the Control group.

10.1371/journal.pone.0090352.t002

###### Daily dietary intakes at baseline and during the intervention (mean ± SD).

![](pone.0090352.t002){#pone-0090352-t002-2}

                           HealthyDiet n = 36   WGED n = 34   Control n = 35                                                                              
  ----------------------- -------------------- ------------- ---------------- ------------- ----------- ----------- ------------ ------------ ----------- -----------
  Energy (kJ)                  8386±2196         9146±2206        0.053           0.121      6995±2373   7654±2395     0.119        0.204      7282±2011   8533±1693
  Total fat (E%)                32.5±6.2         30.5±4.6         0.064           0.129      33.6±5.2    31.1±6.3      0.012        0.043      31.3±5.3    31.9±5.9
  SAFA (E%)                     12.0±3.1         10.8±2.5         0.034           0.090      12.3±2.4    11.1±2.8      0.024        0.070      12.0±2.6    12.1±2.7
  MUFA (E%)                     10.6±2.6          9.5±1.9         0.171           0.261      11.3±2.1     9.8±2.7      0.020        0.065      10.2±2.4     9.9±2.6
  PUFA (E%)                     5.6±1.5           5.4±1.2         0.011           0.043       6.0±1.6     5.0±1.5      0.902        0.962       5.6±1.5     4.6±1.2
  Linoleic acid (E%)            3.78±1.2         3.32±1.02        0.310           0.381      4.27±1.39   3.34±1.32     0.434        0.515      3.83±1.09   3.18±0.85
  α-linolenic acid (E%)        0.84±0.29         1.07±0.28     2.0×1010^−6^    2.2×10^−5^    0.89±0.30   0.74±0.33     0.763        0.842      0.86±0.40   0.71±0.23
  EPA                          0.15±0.13         0.22±0.09        0.002           0.010      0.14±0.24   0.12±0.13     0.180        0.262      0.10±0.10   0.06±0.05
  DHA                          0.35±0.28         0.59±0.27        0.002           0.010      0.30±0.35   0.31±0.29     0.157        0.251      0.22±0.24   0.17±0.13
  Protein (E%)                  18.0±3.1         18.5±2.3         0.210           0.280      19.1±3.2    18.8±2.5      0.950        0.980      18.8±3.7    18.3±2.5
  Carbohydrate (E%)             46.6±7.1         48.1±5.8         0.194           0.270      45.6±6.3    47.2±7.5      0.268        0.343      47.8±5.6    47.3±5.1
  Fiber (g)                     29.2±8.2         36.4±6.3      4.3×10^−13^     1.4×10^−11^   24.6±7.0    26.5±5.4    2.7×10^−7^   4.3×10^−6^   22.5±7.0    18.0±4.2
  Sucrose (E%)                  7.2±2.7           6.2±2.0         0.121           0.204       5.8±2.6     5.3±2.6      0.619        0.707       6.2±2.7     5.9±2.2
  Cholesterol (mg)              274±119           258±148         0.396           0.124       228±106     244±123      0.160        0.981       230±105     256±103
  Alcohol (E%)                  2.9±4.8           3.0±4.8         0.659           0.838       1.6±2.9     3.0±4.5      0.203        0.435       2.1±4.1     2.5±3.2

Based on a 4-day food record at baseline, ^2^Based on three 4-day food records (weeks 3, 7 and 11). ^3^Based on a mixed model comparison, where the interaction of time and group compared to Controls (time\*group) is analyzed.

Serum NMR metabolomics {#s3c}
----------------------

Mixed model analyses revealed significant differences in lipid metabolites when comparing HealthyDiet group to the Control group ([Figure 2](#pone-0090352-g002){ref-type="fig"}). All changes reflected increased polyunsaturation in plasma fatty acids. For example, ratio of bisallylic groups to double bonds (FDR p  =  3×10^−5^), ratio of bisallylic groups to total fatty acids (FDR p =  4×10^−4^) and average number of double bonds in fatty acid chain (FDR p =  0.024) increased and average number of methylene groups per double bonds decreased (FDR p =  0.012) in the HealthtyDiet group compared to the Control group. Bisallylic group has chemical structure of -CH = CH-CH2-CH = CH-, i.e. a single methylene group between the two double bonds and it reflects the level of polyunsaturation in fatty acids. Increases were seen especially in n-3 PUFAs, while n-6 and n-7 fatty acids decreased in the HealthyDiet group compared to the Control group, reflecting the good compliance to fish intake ([Figure 2](#pone-0090352-g002){ref-type="fig"}). The above mentioned differences existed also when comparing HealthyDiet group to WGED group. There were no significant changes in detected metabolites in the WGED compared to the Control group.

![Fold changes in lipid variables at the end of the 12-week intervention period.\
Bars represent mean ± SD. FDR p-values are based on mixed model comparisons, where the interaction of time and group compared to Controls (time\*group) or only the effect of time within a group is tested. HealthyDiet n =  37, Whole grain enriched diet (WGED) n =  34 and Control n = 32.](pone.0090352.g002){#pone-0090352-g002}

There were no significant changes (FDR p \< 0.05) in the metabolic measures quantified from the LIPO- and LMWM-windows (metabolites listed in the Supplemental [table 1](#pone-0090352-t001){ref-type="table"}). However, in within-the-group comparisons we found and increasing trend (FDR p = 0.03 -- 0.08) in variables related to large HDL particles in the HealthyDiet group (data not shown). The changes in concentrations of large HDL particles, in average diameter of HDL particles and in concentrations of lipid components of the large HDL particles associated positively with the changes in fish intake and changes in serum n-3 fatty acids concentrations ([Table 3](#pone-0090352-t003){ref-type="table"}). When participants were divided into tertiles according to changes in fish intake we found that concentration of large HDL particles, mean diameter of HDL particles and serum concentrations of the lipid components of large HDL particles differed between these tertiles ([Figure 3](#pone-0090352-g003){ref-type="fig"}). The daily intake of fish decreased in the first tertile (average change: -- 40 g/d, average intake during the intervention period: 26 g/d), remained nearly unchanged in the second tertile (average change: + 5 g/d, average intake: 28 g/d), and increased in the third tertile (average change: + 62 g/d, average intake: 74 g/d). The most of the consumed fish was fatty. Separation into tertiles based on changes in fish intake did not correspond exactly to the separation of intervention groups. However, most of the subjects (19 of 36) in the third tertile were from the HealthyDiet group as could be expected. There were no differences in changes in concentrations of total, LDL and HDL cholesterol and Tg between the tertiles ([Figure S1](#pone.0090352.s001){ref-type="supplementary-material"}).

![HDL particles and fatty fish intake.\
Changes in concentration of large HDL particles, mean particle diameter of HDL and serum concentrations of large HDL lipid components (mean ± SEM) according to tertiles of changes in fish intake. Changes in fish intake are calculated from 4-d food records which were kept once at baseline and three times during the intervention period.](pone.0090352.g003){#pone-0090352-g003}

10.1371/journal.pone.0090352.t003

###### Associations[1](#nt103){ref-type="table-fn"} between changes in fish intake, and changes in plasma n-3 fatty acid and DHA concentrations and changes in concentrations of very large and large HDL particles, average diameter of HDL particles and concentrations of large HDL lipid components in all study participants (n = 105).

![](pone.0090352.t003){#pone-0090352-t003-3}

                                                   Total fish ^2^   Fatty fish ^2^   n-3 fatty acids ^3^   DHA ^3^                                                          
  ----------------------------------------------- ---------------- ---------------- --------------------- --------- ------- ------- ------- ------- ------- ------- ------- -------
  Concentration of very large HDL particles ^3^        0.269            0.011               0.019           0.232    0.030   0.117   0.414   0.001   0.008   0.277   0.020   0.038
  Concentration of large HDL particles ^3^             0.268            0.012               0.019           0.178    0.102   0.117   0.318   0.011   0.016   0.271   0.024   0.038
  Mean diameter for HDL particles ^3^                  0.279            0.008               0.019           0.227    0.018   0.117   0.308   0.012   0.016   0.245   0.039   0.052
  Total lipids in large HDL ^3^                        0.268            0.012               0.019           0.178    0.102   0.117   0.318   0.011   0.016   0.271   0.024   0.038
  Phospholipids in large HDL ^3^                       0.258            0.017               0.023           0.154    0.164   0.164   0.248   0.050   0.050   0.202   0.098   0.098
  Total cholesterol in large HDL ^3^                   0.228            0.029               0.033           0.197    0.064   0.117   0.349   0.004   0.011   0.319   0.006   0.024
  Cholesterol esters in large HDL ^3^                  0.198            0.057               0.057           0.187    0.077   0.117   0.345   0.004   0.011   0.335   0.004   0.024
  Free cholesterol in large HDL ^3^                    0.288            0.007               0.019           0.199    0.068   0.117   0.307   0.014   0.016   0.221   0.068   0.078

Analysis of covariance (ANCOVA) using standardized variables. Age, BMI, gender, fasting glucose and group are included into the model, ^2^ Absolute change during the intervention, (g/d), ^3^ Changes in plasma concentration,

We also tested the cross-sectional associations at baseline and at the end of the study between mean diameters of HDL and LDL particles and the serum Tg concentration in all participants, and we found negative associations between the mean diameter of HDL and serum Tg concentration (beta = --0.410, p = 1.8×10^−5^ at baseline, beta = --0.320, p = 0.004 at the end), and the mean diameter of LDL and serum Tg concentration (beta = --0.380, p = 5.2×10^−6^ at baseline, beta = --0.572, p = 3.8×10^−10^ at the end). The associations were adjusted with BMI, age, gender and fasting glucose concentration at baseline and BMI, age, gender, fasting glucose concentration and intervention group at the end of the study.

PON1 and lipid transfer protein activities {#s3d}
------------------------------------------

There were no significant changes in PLTP, CETP and PON1 activities during the intervention ([Table 1](#pone-0090352-t001){ref-type="table"}). There was a slight positive association between CETP and PLTP activities and the variables related to extra-large HDL particles at baseline, but adjusted FDR p-values were not significant ([Table 4](#pone-0090352-t004){ref-type="table"}). These associations were not seen at the end of the study. Further, we observed no correlations between PON1 activity and HDL particle variables at baseline or at the end of the study or between changes in lipid transfer protein activities and changes in HDL particle variables during the intervention period.

10.1371/journal.pone.0090352.t004

###### Regressions[1](#nt104){ref-type="table-fn"} between CETP, PLTP activities and variables related to HDL particles at baseline.
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                                                CETP     PLTP                                     
  ------------------------------------------- --------- ------- ------- --------- ------- ------- -----
  Fasting plasma HDL cholesterol (total)        0.051    0.640   0.668    0.144    0.190   0.304   106
  Mean diameter for HDL particles               0.203    0.068   0.264    0.226    0.045   0.154   103
  Concentration of very large HDL particles     0.220    0.042   0.240    0.227    0.037   0.148   103
  Total lipids in very large HDL                0.213    0.050   0.240    0.243    0.026   0.148   101
  Total cholesterol in very large HDL           0.230    0.031   0.240    0.273    0.011   0.132   101
  Cholesterol esters in very large HDL          0.234    0.029   0.240    0.297    0.006   0.132   101
  Free cholesterol in very large HDL            0.238    0.026   0.240    0.230    0.033   0.148   101
  Phospholipids in very large HDL               0.193    0.077   0.264    0.201    0.068   0.204   101
  Triglycerides in very large HDL              --0.001   0.991   0.991    0.238    0.030   0.148   103
  Concentration of large HDL particles          0.102    0.363   0.484    0.163    0.150   0.285   103
  Total lipids in large HDL                     0.108    0.336   0.484    0.165    0.144   0.285   103
  Total cholesterol in large HDL                0.119    0.282   0.484    0.171    0.125   0.285   103
  Cholesterol esters in large HDL               0.107    0.334   0.484    0.175    0.115   0.285   103
  Free cholesterol in large HDL                 0.147    0.179   0.484    0.154    0.166   0.285   103
  Phospholipids in large HDL                    0.097    0.388   0.490    0.158    0.163   0.285   103
  Concentration of medium HDL particles        --0.103   0.344   0.484   --0.001   0.990   0.990   103
  Total lipids in medium HDL                   --0.108   0.326   0.484   --0.012   0.912   0.990   101
  Total cholesterol in medium HDL              --0.121   0.259   0.484   --0.037   0.737   0.931   101
  Cholesterol esters in medium HDL             --0.127   0.233   0.484   --0.050   0.640   0.853   101
  Free cholesterol in medium HDL               --0.080   0.471   0.514    0.005    0.968   0.990   101
  Phospholipids in medium HDL                  --0.081   0.467   0.514    0.020    0.856   0.978   101
  Concentration of small HDL particles         --0.108   0.280   0.484   --0.100   0.323   0.485   103
  Total lipids in small HDL                    --0.103   0.305   0.484   --0.086   0.397   0.560   101
  Triglycerides in small HDL                   --0.070   0.471   0.514    0.023    0.814   0.977   101

Linear regression model; age, BMI, fasting glucose and gender included into the model.

Discussion {#s4}
==========

In the present study the effects of diets containing fatty fish, wholegrain and low insulin response grain products, and bilberries on clinical characteristics, serum metabolites and lipid transfer protein activities in persons with impaired glucose metabolism were investigated. We found significant changes in lipid metabolites in the HealthyDiet group reflecting increased polyunsaturation of plasma fatty acids, particularly increase in n-3 PUFAs. Furthermore, in the within-the-group comparisons we found an increasing trend in variables related to large HDL particles in the HealthyDiet group, and when analysing this in more detail we found that the increase of fish intake correlated strongly with the increased concentration of large HDL particles, larger average diameter of HDL particles and increased concentrations of large HDL lipid components.

Significant changes in lipid metabolites in the HealthyDiet group were observed. All changes reflected increased polyunsaturation in plasma fatty acids, especially increase in n-3 PUFAs, while n-6 and n-7 fatty acids decreased. This is consistent with our earlier findings of increased plasma content of long chain polyunsaturated n-3 fatty acids and increase of plasma Tg incorporating the long chain PUFA in the HealthyDiet group [@pone.0090352-Lankinen1]. These findings also confirm that different analytical methods (gas chromatography, UPLC-MS and ^1^H-NMR), give consistent results for comparable lipid measures. The observed changes confirm the good compliance to the instructions of fish intake, since the subjects in the HealthyDiet group were advised to eat fatty fish at least three times per week, whereas subjects in the Control group where instructed to restrict their fish intake for maximum of 1 fish meal per week. In the WGED group, dietary habits, besides the cereal products, were advised to keep unchanged, which did not cause changes in the measured metabolites.

Serum total, LDL and HDL cholesterol levels, serum Tg or serum apoA-1 and apoB100 concentrations did not change during the intervention. We observed that a greater increase of fish intake was associated with increased concentration of large HDL particles, larger average diameter of HDL particles and increased concentrations of lipid components in large HDL particles. This is consistent with earlier findings of increases in large HDL particles and/or decreases of small particles after consumptions of fatty fish or fish oil supplements [@pone.0090352-Burillo1]. The effects of n-3 PUFA on HDL metabolism has been studied in several randomized controlled trials, and the most of the studies suggest putative antiatherogenic changes, with increases of large HDL particles and/or decreases of small HDL particles [@pone.0090352-Pirillo1], [@pone.0090352-Burillo1]. Nearly all studies have been conducted with fish oil supplements instead of fish consumption as part of the diet. It has also been shown that EPA and DHA supplementation improves reverse cholesterol transport (RCT) from macrophage to feces in hamsters fed with high fat diet [@pone.0090352-KasbiChadli1]. Our findings of larger average diameter of HDL particles and increased concentration of large and extra-large HDL particles within the tertile with greatest increase in fish intake are consistent with earlier results [@pone.0090352-Burillo1]. We also observed an association between changes in fish intake and changes in concentrations of total lipids, phospholipids, total cholesterol, cholesterol esters and free cholesterol in large HDL. However, based on this data we are not able to conclude if this reflects changes in the content of large HDL particles or only increased serum concentration of large HDL particles. ApoA-1 and total HDL concentrations did not change during the intervention, which may be related to the trend of a decrease in small HDL particles (data not shown), that may compensate increases in larger particles.

Modern genome-wide and Mendelian randomization studies have failed to show a causal link between total HDL cholesterol concentration and coronary artery disease [@pone.0090352-CARDIoGRAMplusC4D1], [@pone.0090352-Haase1], which might be related to the fact, that HDL is a heterogenous pool of subpopulations which differ in their structure and function [@pone.0090352-Rye1]. In atherosclerosis-related diseases, variations in subpopulation levels and functions are observed, supporting the general view that the concentration of large HDL particles is inversely associated while that of small HDL particles is positively associated with cardiovascular disease [@pone.0090352-Pirillo1], [@pone.0090352-Burillo1]. In addition, Gordon et al recently reported that the phospholipid content of large HDL subfractions showed a significant inverse correlation with the vascular stiffness assessed using pulse wave velocity [@pone.0090352-Gordon1]. In addition to this arterial stiffness measurements, cholesterol efflux from human THP-1 macrophages has been shown to correlate with phospholipids and particle mass of HDL demonstrating that the phospholipid content of HDL is an important determinant of cholesterol efflux [@pone.0090352-Nakanishi1]--[@pone.0090352-Fournier1]. Furthermore, the effect of HDL particle size on efflux capacity, and the impact of large HDL particles on cholesterol removal strongly suggest their protective role against the development of atherosclerosis [@pone.0090352-Davidson1], [@pone.0090352-Matsuura1]. The association between hypertriglyceridemia and CVD risk is also controversial and is weakened when adjustment is made for other risk factors [@pone.0090352-CARDIoGRAMplusC4D1], [@pone.0090352-Graham1]. Here we found cross-sectional negative correlations between serum Tg concentration and average diameter of HDL and LDL particles, a finding that is also evident in metabolic syndrome [@pone.0090352-Soderlund1]. This suggests that the known effect of serum Tg concentration on increased risk of CVD or type 2 diabetes may in part be related to altered HDL metabolism [@pone.0090352-Wang1].

The relationship between CETP and lipoprotein metabolism is complex [@pone.0090352-Parra1], [@pone.0090352-Barter1]. CETP is central in cholesterol and Tg transport between HDL and apoB-containing lipoproteins in the circulation, and this CETP-mediated lipid transfer clearly differs in various dyslipidemias [@pone.0090352-deGrooth1]. CETP simultaneously affects the concentration and composition of both antiatherogenic and atherogenic lipoproteins and its connection to coronary heart disease risk is not completely understood [@pone.0090352-deGrooth1]. No changes in the lipid transfer protein activities during the 12-week dietary intervention were observed. Earlier results of the effects of fish oil treatment on CETP activity are discordant, which might be related to the type of fish oil studied (EPA vs. DHA) [@pone.0090352-Abbey1], [@pone.0090352-Homma1]. We found weak positive association between CETP and PLTP activities and mean particle diameter of HDL and other variables related to extra-large HDL particles at baseline. Overall, CETP can be seen as one among the factors affecting reverse cholesterol transport pathway and high CETP activity is reportedly associated with decreased HDL cholesterol levels [@pone.0090352-deGrooth1]. CETP inhibitors have recently gained great interest due to their ability to increase HDL cholesterol concentration, but it remains to be seen whether their use will result in functionally protective HDL populations and clinical benefit in large trials [@pone.0090352-Bishop1].

Although the effects of intervention on clinical characteristics and measured metabolites were modest, we found a strong association between increased fish intake and variables related to large HDL particles. However, as a potential limitation, our study design does not allow for total separation of fish intake from increased intake of whole grain and low insulin response grain products and bilberries, but this was considered in statistical analyses by including the intervention group into the model. In fact, not all subjects in the third tertile with the greatest increase in fish intake were in the HealthyDiet group. The average consumption of fish was 74 grams per day in the third tertile, which is more than 500 g per week. This suggests that the instructed three fish meals per week were not enough for these changes. The mean consumption of fish in the third tertile was more than double of average fish consumption among the Finnish population [@pone.0090352-Paturi1]. We have seen that people who are willing to participate in dietary interventions are more interested in healthy eating than people in average. This phenomenon is also observed when comparing the baseline nutrient intakes in the present study with the respective average intakes in Finland (e.g. lower intake of SFA and sucrose and higher intake of dietary fiber in the study population) [@pone.0090352-Paturi1]. This is one obvious explanation why it might be difficult to see significant changes in the intervention groups with healthy diet. For the same reason, people in the Control group had to limit their rye bread, fish and berry intake, so that the control diet resembled more an average Finnish diet. For example, rye bread intake in men in the Northern Savo area is more than double compared to corresponding intake in Southern Finland [@pone.0090352-Paturi1].

Besides lipoprotein subclass distribution and detailed information on serum lipids, the NMR platform enables detection of low-molecular-weight metabolites including e.g. citrate, acetate, urea and amino acids. We did not see changes in these 22 measured metabolites during the intervention. The battery of 22 low-molecular-weight metabolites was not selected particularly for this dietary intervention study and we did not have preliminary hypothesis related to these metabolites. Furthermore, the power calculation was based on fasting glucose concentration, and it is possible that there was not enough power to see all changes in these secondary outcome variables. Of these metabolites, branched chain amino acids were probably the most interesting ones, because they are related to type 2 diabetes risk and we have earlier found that serum isoleucine decreased after the 12 week consumption of diet high in rye bread and pasta [@pone.0090352-Wang2], [@pone.0090352-Lankinen2]. Despite similar carbohydrate modification of the diet in the HealthyDiet and WGED groups of the present study (increasing the intakes of rye bread and pasta), we could not see any changes in isoleucine. This confirms our earlier conclusion that decreased isoleucine may rather be due to decreased intake of protein rich foods, which are also sources of isoleucine, than the intervention itself. In the current study, there were no changes in protein intake during the intervention period.

In conclusion, increased fatty fish intake was associated with beneficially considered changes in HDL particles in persons at risk for coronary heart disease. The changes which we saw in large HDL particles could be related to those parameters that are functionally related to reverse cholesterol transport. Thus, our findings could partly explain the known protective effects of fish consumption against the atherosclerosis.
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